Leonard Zehr, Author at BioTuesdays

Feature

BioCardia developing autologous and allogenic cardiovascular cell therapies

BioCardia (NASDAQ:BCDA) is developing two late-stage clinical autologous cell therapies, known as CardiAMP, for ischemic heart failure and chronic myocardial ischemia, a neurokinin 1 receptor positive (NK1R+) allogenic...

September 15, 2020

Feature

Profound Medical’s TULSA-PRO and Sonalleve treatments at a Center of Excellence at the University Hospital of Cologne

By Leonard Zehr The University Hospital of Cologne is one of the largest in Germany with 59 departments and institutions, and is a leading interdisciplinary Oncology Center of Excellence. Recently, the interdisciplinary...

September 8, 2020

Feature

Profound Medical’s TULSA-PRO prostate cancer treatment finds early adopter in Dr. Joseph Busch

As the founder of Atlanta’s renowned Busch Center, Dr. Joseph Busch Jr. brings a 40-year-plus track record in diagnostic radiology and hundreds of international research studies to preventative screening and accurate...

August 11, 2020

Feature

Prothena building diverse pipeline in multiple neurodegenerative and rare indications

Fueled by decades of research in protein dysregulation and fundamental neuroscience, Prothena (NASDAQ:PRTA) is advancing a pipeline of therapeutic candidates with the potential to change the course of diseases such as...

August 4, 2020

Feature

InspireMD advancing global distribution of CGuard EPS carotid stent for stroke prevention; gearing for U.S. pivotal trial

InspireMD (NYSE American:NSPR) is awaiting a decision from the FDA for an investigational device exemption as a steppingstone for a pivotal trial of its CE Mark-approved CGuard Carotid Stent System for the prevention of...

July 28, 2020

Feature

Soliton seeking FDA okay to treat cellulite with Rapid Acoustic Pulse

Soliton (NASDAQ:SOLY) has filed a 510(k) submission for FDA clearance of its Rapid Acoustic Pulse (RAP) technology for reduction in the appearance of cellulite, which affects between 80% and 90% of women. The FDA has...

July 21, 2020

Feature

Loki Therapeutics harnessing antigens from traditional childhood vaccinations for immunotherapy

Unlike the traditional approach to immunotherapy, which teaches the body to recognize tumor antigens as something foreign to be attacked, closely-held Loki Therapeutics’ AWAKE technology makes cancer appear as something...

July 7, 2020

Feature

CohBar developing therapeutics from mitochondrial DNA

CohBar (NASDAQ:CWBR) is transforming peptides encoded and expressed by mitochondria, some of which control a wide range of systems in the body, into novel therapeutics. “Harnessing the power of mitochondria biology to...

June 23, 2020

Feature

Seven questions for Ian Koenig of Investis Digital about expediting patient recruitment for clinical trials

In his role as SVP of life sciences, Ian Koenig brings broad experience to Investis Digital in communications strategy, digital marketing, investor relations and business development on behalf of biopharma globally. Mr...

June 9, 2020

Feature

Chris Kaplan of ITG talks up market-making in capital markets

As a VP of Independent Trading Group (ITG), an issuer designated market making firm, Chris Kaplan brings a more institutional approach to provide liquidity for clients with stocks that are thinly traded. ITG, which is...

June 2, 2020

Author - Leonard Zehr

BioCardia developing autologous and allogenic cardiovascular cell therapies

Profound Medical’s TULSA-PRO and Sonalleve treatments at a Center of Excellence at the University Hospital of Cologne

Profound Medical’s TULSA-PRO prostate cancer treatment finds early adopter in Dr. Joseph Busch

Prothena building diverse pipeline in multiple neurodegenerative and rare indications

InspireMD advancing global distribution of CGuard EPS carotid stent for stroke prevention; gearing for U.S. pivotal trial

Soliton seeking FDA okay to treat cellulite with Rapid Acoustic Pulse

Loki Therapeutics harnessing antigens from traditional childhood vaccinations for immunotherapy

CohBar developing therapeutics from mitochondrial DNA

Seven questions for Ian Koenig of Investis Digital about expediting patient recruitment for clinical trials

Chris Kaplan of ITG talks up market-making in capital markets

General

More